PARP1 and breast carcinoma: Here, we demonstrate, for the first time, that SOC therapies used in ER+ breast cancer induce DNA damage, and toxic PARP1 trapping upon generation of a functional BRCAness phenotype through loss of key DNA repair proteins, including BRCA1, BRCA2 and RAD51.